BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated by Analysts at

Research analysts at started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) in a report released on Monday. The firm set a “sell” rating on the stock.

BiondVax Pharmaceuticals Stock Performance

Shares of BVXV stock opened at $0.87 on Monday. The company has a debt-to-equity ratio of 11.62, a quick ratio of 1.71 and a current ratio of 1.71. BiondVax Pharmaceuticals has a one year low of $0.53 and a one year high of $3.49. The company has a 50 day moving average price of $0.82 and a 200 day moving average price of $1.08. The firm has a market capitalization of $12.47 million, a price-to-earnings ratio of -1.43 and a beta of 2.36.

BiondVax Pharmaceuticals’s stock is scheduled to reverse split before the market opens on Friday, November 25th. The 1-10 reverse split was announced on Friday, November 25th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, November 25th.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last announced its earnings results on Thursday, August 25th. The company reported ($0.21) earnings per share for the quarter. Sell-side analysts anticipate that BiondVax Pharmaceuticals will post -0.02 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. increased its position in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) by 226.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 163,423 shares of the company’s stock after purchasing an additional 113,418 shares during the quarter. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 2.94% of the company’s stock.

About BiondVax Pharmaceuticals

(Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Featured Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.